The good, the bad and the ugly red tape of biomedical research. How could regulators lower bureaucratic hurdles in clinical research without compromising the safety of patients?
Greener
Mark
M
D035843:Biomedical Research / Q000331:legislation & jurisprudence* / Q000592:standards; D015316:Genetic Therapy; D006801:Humans; D008004:Licensure; D010344:Patient Advocacy / Q000331:legislation & jurisprudence* / Q000592:standards*; D012449:Safety / Q000331:legislation & jurisprudence* / Q000592:standards; D013234:Stem Cells